PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis

Cancer Prevention Research

Volumn 7, Issue 4, 2014, Pages 407-417

  So, Po Lin ^a,c   Wang, Grace Y ^a   Wang, Kevin ^a   Chuang, Mindy ^a   Chiueh, Venice Calinisan ^b   Kenny, Paraic A ^d   Epstein Jr , Ervin H ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE B; RETINOIC ACID RECEPTOR GAMMA; TAZAROTENE; XL 147; XL 765; ENZYME INHIBITOR; KERATOLYTIC AGENT; MESSENGER RNA; NICOTINIC ACID DERIVATIVE; RETINOID; TUMOR MARKER;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BASAL CELL CARCINOGENESIS; BASAL CELL CARCINOMA; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVE SITE; GENE EXPRESSION; GENE PROBE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SECOND MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; APOPTOSIS; CARCINOMA, BASAL CELL; CELL TRANSFORMATION; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; CARCINOMA, BASAL CELL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; KERATOLYTIC AGENTS; MICE; NICOTINIC ACIDS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RETINOIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84898841252     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0304     Document Type: Article

References (43)

1. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 2008;58:S129-32. (Pubitemid 351506511)
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
3. Aszterbaum M, Epstein J, Oro A, Douglas V, LeBoit PE, Scott MP, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 1999;5:1285-91. (Pubitemid 29535606)
4. Mancuso M, Pazzaglia S, Tanori M, Hahn H, Merola P, Rebessi S, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-defi cient mice. Cancer Res 2004;64:934-41. (Pubitemid 38176895)
5. Schmuth M, Watson RE, Deplewski D, Dubrac S, Zouboulis CC, Griffiths CE. Nuclear hormone receptors in human skin. Horm Metab Res 2007;39:96-105. (Pubitemid 46535567)
6. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006;54:933-46; quiz 47-50.
7. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000;6:919-31. (Pubitemid 30409389)
8. So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther 2008;7:1275-84.
9. So PL, Lee K, Hebert J, Walker P, Lu Y, Hwang J, et al. Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004;64:4385-9. (Pubitemid 38856905)
10. Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004;151:148-56. (Pubitemid 39061292)
11. Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, Chanana AM, Lee W, et al. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Cancer Prev Res 2014;7:292-9.
12. So PL, Langston AW, Daniallinia N, Hebert JL, Fujimoto MA, Khaimskiy Y, et al. Long-term establishment, characterization and manipulation of cell lines from mouse basal cell carcinoma tumors. Exp Dermatol 2006;15:742-50. (Pubitemid 44145244)
13. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93. (Pubitemid 36181903)
14. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:2110-5. (Pubitemid 29117876)
15. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal 2009;7:e005.
16. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999;9:140-7. (Pubitemid 29158546)
17. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009;9:873-86.
18. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007;104:5895-900.
19. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, et al. A role of PDGFRa in basal cell carcinoma proliferation. Proc Natl Acad Sci U S A 2001;98:9255-9. (Pubitemid 32743903)
20. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
21. Lin N, Moroi Y, Uchi H, Fukiwake N, Dainichi T, Takeuchi S, et al. Signi ficance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis. J Dermatol Sci 2007;48:71-3. (Pubitemid 47284806)
22. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404:15-21. (Pubitemid 46788080)
23. Foster PG, Exelixis. Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. AACR-NCI-EORTIC International Conference, Molecular Targets and Cancer Therapeutics Discovery, Biology, and Clinical Applications; 2007 October 22-26, 2007.
24. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003;17:1794-805. (Pubitemid 37185255)
25. Patnaik A, LoRusso P, Tabernero J, Laird D, Aggarwal K, Papadopoupos K. Biomarker development for XL-765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a phase I clinical trial. Presented at: 19th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics San Francisco, CA, USA, 2007.
26. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32.
27. Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 2011;19:114-24.
28. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004;131:217-28. (Pubitemid 38111428)
29. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, et al. Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep 2006;15:1141-5.
30. Ingram WJ, Wicking CA, Grimmond SM, Forrest AR, Wainwright BJ. Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene 2002;21:8196-205. (Pubitemid 35454424)
31. Villani RM, Adolphe C, Palmer J, Waters MJ, Wainwright BJ. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res 2010;3:1222-34.
32. Mizuarai S, Kawagishi A, Kotani H. Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines. Mol Cancer 2009;8:44.
33. Riobo NA, Lu K, Ai X, Haines GM, Emerson CP Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A 2006;103:4505-10.
34. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 2009;69:2550-8.
35. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70.
36. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012;21:374-87.
37. Bastien J, Plassat JL, Payrastre B, Rochette-Egly C. The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene 2006;25:2040-7.
38. Doi T, Sugimoto K, Ruttenstock E, Dingemann J, Puri P. Prenatal retinoic acid upregulates pulmonary gene expression of PI3K and AKT in nitrofen-induced pulmonary hypoplasia. Pediatr Surg Int 2010;26:1011-5.
39. Lopez-Carballo G, Moreno L, Masia S, Perez P, Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 2002;277:25297-304. (Pubitemid 34951839)
40. Athar M, Kopelovich L. Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res 2011;4:957-61.
41. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39.
42. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007;67:7960-5. (Pubitemid 47395125)
43. Fan QW, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 2010;347:279-96.